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Abstract
Introduction Metabolic profiling of cerebrospinal fluid (CSF) is a promising technique for studying brain diseases. Measure-
ments should reflect the in vivo situation, so ex vivo metabolism should be avoided.
Objective To investigate the effects of temperature (room temperature vs. 4 °C), centrifugation and ethanol, as anti-enzymatic 
additive during CSF sampling on concentrations of glutamic acid, glutamine and other endogenous amines.
Methods CSF samples from 21 individuals were processed using five different protocols. Isotopically-labeled alanine, 
isoleucine, glutamine, glutamic acid and dopamine were added prior to sampling to trace any degradation. Metabolomics 
analysis of endogenous amines, isotopically-labeled compounds and degradation products was performed with a validated 
LC–MS method.
Results Thirty-six endogenous amines were quantified. There were no statistically significant differences between sampling 
protocols for 31 out of 36 amines. For GABA there was primarily an effect of temperature (higher concentrations at room 
temperature than at 4 °C) and a small effect of ethanol (lower concentrations if added) due to possible degradation. O-phos-
phoethanolamine concentrations were also lower when ethanol was added. Degradation of isotopically-labeled compounds 
(e.g. glutamine to glutamic acid) was minor with no differences between protocols.
Conclusion Most amines can be considered stable during sampling, provided that samples are cooled immediately to 4 °C, 
centrifuged, and stored at − 80 °C within 2 h. The effect of ethanol addition for more unstable metabolites needs further 
investigation. This was the first time that labeled compounds were used to monitor ex vivo metabolism during sampling. 
This is a useful strategy to study the stability of other metabolites of interest.
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Abbreviations
CSF  Cerebrospinal fluid
LC–MS  Liquid chromatography–mass spectrometry
ILC  Isotopically-labeled compounds
ISTD  Internal standard
PE  O-phosphoethanolamine
GABA  Gamma-aminobutyric acid butyric acid
1 Introduction
Novel high-throughput biochemical analysis technologies 
used in metabolomics and proteomics allow for large-scale 
profiling of metabolites and proteins in body fluids (Bag-
german et al. 2004; Patti et al. 2012; Schutzer et al. 2010). 
With their advent there is growing interest in using cerebro-
spinal fluid (CSF) as a relatively easy accessible source for 
Marek J. Noga, Ronald Zielman, Thomas Hankemeier and Michel 
D. Ferrari have contributed equally to the manuscript.
Electronic supplementary material The online version of this 
article (https ://doi.org/10.1007/s1130 6-018-1333-0) contains 
supplementary material, which is available to authorized users.
 * Thomas Hankemeier 
 hankemeier@lacdr.leidenuniv.nl
1 Division of Analytical Biosciences, Leiden Academic Centre 
for Drug Research, Leiden University, Einsteinweg 55, 
2333 CC Leiden, The Netherlands
2 Department of Neurology, Leiden University Medical Centre, 
Leiden, The Netherlands
3 Department of Human Genetics, Leiden University Medical 
Centre, Leiden, The Netherlands
 M. J. Noga et al.
1 3
44 Page 2 of 10
the discovery of biomarkers reflecting biochemical changes 
in the dysfunctional brain (Zhang et al. 2013). Wide-scale 
“CSF-omics” studies aim to reveal novel biochemical path-
ways for brain diseases (Mitchell et al. 2009; Nishino et al. 
2001), and to provide diagnostic (Duits et al. 2014; Spies 
et al. 2013) and prognostic biomarkers (Hansson et al. 2006; 
Stewart et al. 2014).
In addition to the technological challenge to continuously 
increase coverage, sensitivity, specificity and throughput of 
the analytical methods, stability of the metabolites during 
and after sampling is of major importance (Anesi et al. 1998; 
Levine et al. 2000), but largely ignored. After all, ex vivo 
changes of unstable compounds could occur due to enzy-
matic or chemical reactions (Anesi et al. 1998; Del Campo 
et al. 2012; Schoonenboom et al. 2005). In clinical practice, 
CSF is often sampled using protocols designed for routine 
clinical measurements (i.e. cell count, total protein, glucose) 
and not specifically for metabolomics or proteomics. Sam-
ples are primarily transported at room temperature and time 
until analysis and subsequent storage of remaining CSF in 
the freezer can vary significantly. This increases the risk of 
ex vivo biochemical changes that may occur after withdrawal 
of the CSF, and potentially reducing the comparability with 
samples from other studies when non-routine measurements 
such as metabolomics or proteomics are performed (Vander-
stiechele et al. 2012).
Previously published consensus guidelines for CSF 
sampling have already established some main pre-analyt-
ical factors that should be standardized (Del Campo et al. 
2012; Teunissen et al. 2009; Vanderstiechele et al. 2012). 
However, the scientific basis for this guideline was mainly 
based on stability studies that focused on protein biomark-
ers (for Alzheimer’s disease and Parkinson’s disease), i.e. 
these guidelines do not have recommendations for samples 
used for metabolomics studies. For the CSF metabolome, 
major factors that can cause ex vivo biochemical changes 
include the temperature during sampling and processing, 
additional procedures such as centrifugation to remove cells, 
and the use of additives to stabilize the metabolic profile 
(Del Campo et al. 2012). It is especially important to deter-
mine these factors for metabolites which function as neuro-
transmitter or neurotransmitter precursors, since these are 
of primary interest for most brain disorders. Concentrations 
of glutamic acid, the major excitatory neurotransmitter of 
the brain (Danbolt 2001), could be unstable in CSF because 
of potential ex vivo degradation of its precursor glutamine 
(Anesi et al. 1998; Ferrarese et al. 1993). However, so far 
this degradation has not been quantified.
The aim of this study was to investigate the effect of 
major sample handling factors (low sampling and process-
ing temperature, centrifugation to remove cells, and addition 
of ethanol to stop enzymatic reactions) on the stability of 
the metabolic profile of primary and secondary endogenous 
amines. To this end we compared five different sample han-
dling protocols for CSF. In addition, we quantified the deg-
radation of allegedly unstable metabolites such as glutamine 
by adding isotopically-labeled versions of these metabolites 
to sampling tubes before CSF sampling.
2  Materials and methods
2.1  CSF sampling procedure
We obtained human CSF samples from 21 individuals 
(16 migraine patients and 5 healthy controls) as part of a 
research program on migraine pathophysiology. The study 
was approved by the Medical Ethical Committee of Leiden 
University Medical Centre (LUMC). All subjects gave writ-
ten informed consent prior to collection.
CSF sampling was performed before 12.00 am via lum-
bar puncture. All subjects were overnight fasted and only 
allowed water in the 8 h preceding lumbar puncture. Local 
skin was disinfected with Chlorhexidine (5 g/L)/denatured 
ethanol 70% (art.no. 909602; Pharmacy LUMC, Leiden, 
the Netherlands). CSF was sampled between the L3/L4, L4/
L5 or L5–S1 interspace with an atraumatic Sprotte® nee-
dle (Pajunk GmbH, Geisingen, Germany). For routine CSF 
diagnostics we collected 3 mL CSF followed by 12 mL for 
migraine research purposes.
2.2  Five different sampling protocols
For this study we additionally collected five times 1 mL CSF 
in five separate 15-mL polypropylene falcon tubes (art.no. 
188271; Greiner Bio-One, Kremsmünster, Austria) that 
already contained a 100-µL mix of isotopically-labeled com-
pounds (ILC-mix; preparation described in 2.3). Tubes were 
inverted at least ten times to mix the CSF and ILC-mix. For 
each of the five tubes there was a unique sample handling 
protocol to study the effects of temperature, centrifugation 
and the addition of ethanol. The five protocols are depicted 
in Fig. 1.
For protocol 1, CSF collection and centrifugation were 
performed at room temperature; for the additional four pro-
tocols sampling tubes were prepared on ice before CSF was 
added and further sample handling was also done on ice. 
For protocol 2, the sampling tube also contained 2 mL cold 
ethanol (ethanol absolute prod. no. 8098; J.T.Baker, Avantor 
Performance Materials, Center Valley, PA, USA) besides the 
ILC-mix. For protocol 3, centrifugation was performed and 
ethanol was later added during aliquoting. For protocol 4, we 
performed no additional sample handling steps. For protocol 
5, the samples were centrifuged.
All centrifugation steps (protocols 1, 3, and 5) were per-
formed for 5 min (2000 rpm, 747 g) directly after sampling. 
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Centrifugation in protocol 1 was performed at 21 °C and for 
protocols 3 and 5 at 4 °C. After centrifugation, the super-
natant was transferred to another 15-mL polypropylene fal-
con tube, and divided in aliquots. Samples from protocols 
1, 4 and 5 were divided in 0.25-mL aliquots [into 0.5-mL 
cryotubes (Eppendorf, Hamburg, Germany)], samples from 
protocols 2 and 3 in 0.75-mL aliquots [into 1.5-mL cryo-
tubes (Eppendorf)] because of the additional ethanol. All 
aliquots were immediately placed on dry ice after process-
ing, within 30–60 min from sampling, and transferred to 
− 80 °C for storage within 120 min from sampling. All sam-
ples remained at − 80 °C until sample preparation, no extra 
freeze–thaw cycles were allowed.
2.3  Compound labeling strategy
To assess whether potential differences between proto-
cols were due to metabolic degradation, and not due to 
other factors, we added ILC-mix containing two stable 
and three potentially unstable compounds to the collec-
tion tubes. Stable isotopically-labeled compounds were: 
2,3-13C2-alanine (ILC-mix: 300 µmol/L; Cortecnet, Voisins-
Le-Bretonneux, France) and 13C15N-isoleucine (ILC-mix: 
30 µmol/L; Cambridge isotope laboratories, Tewksbury, 
MA, USA) (Davis et al. 2009). Potentially unstable com-
pounds were: 1,3-13C2-glutamine (ILC-mix: 5000 µmol/L; 
Cambridge isotope laboratories, Tewksbury, MA, USA), 
 U13C–U15N–UD-glutamic acid (ILC-mix: 125  µmol/L; 
Cambridge isotope laboratories, Tewksbury, MA, USA), 
and 1,2,3,4,5,6-13C6-dopamine (ILC-mix: 1.25 µmol/L; 
CDN Isotopes, Pointe-Claire, Canada). Isotopically-labeled 
compounds were selected to minimize overlap of their iso-
topic envelopes. Concentrations of isotopically-labeled com-
pounds were chosen such that they approximate physiologi-
cal concentrations after addition of CSF. The ILC-mix was 
prepared in one batch, then divided into aliquots, and stored 
at − 80 °C until the day of sampling. Maximal 1 h before 
sampling the ILC-mix was defrosted at room temperature. 
For each subject, we prepared the five 15-mL polypropyl-
ene collection tubes for sampling by adding 100 µL of the 
ILC-mix.
2.4  Measurements of endogenous amines
For the targeted analysis of primary and secondary amines 
we employed a LC–MS method using AccQ-Tag derivatiza-
tion as described before (Noga et al. 2012). Measurements 
were performed with Xevo TQ mass spectrometer (Waters, 
Etten-Leur, The Netherlands) operating with the width of 
the isolation/fragmentation window of 1.2 Da. Cell-free 
U–13C–U15N-labeled amino acid mix (Cambridge isotope 
laboratories),  D4-β-alanine, D6-ornithine,  D4-histamine, 
 D6-2-aminobutyr ic acid,   D3-3-methyl-histidine, 
 D3-3-methoxytyrosine and  D4-3-methoxytyramine (CDN 
Isotopes) were used as internal standards. Acquired data 
were evaluated using MassHunter software (Agilent, Santa 
Clara, CA, USA) by integration of assigned SRM peaks and 
normalization using proper internal standards (ISTDs). For 
analysis of amino acids, their U–13C–U15N-labeled ana-
logues were used as ISTDs. For other amines—the closest-
eluting ISTD was used. Relative concentrations of endog-
enous compounds were reported as response ratios to their 
respective ISTDs. Data quality was monitored and compen-
sated for shifts in sensitivity of the mass spectrometer over 
time using additionally measured quality control (QC) sam-
ples as described before (van der Kloet et al. 2009). Meas-
urement variation was evaluated by calculating the relative 
standard deviation (RSD) per amine from replicate samples 
and QC samples.
2.5  Measurements of isotopically‑labeled stability 
markers
Isotopically-labeled stability markers and degradation prod-
ucts were measured with a modified version of the method 
used for endogenous compounds. Sample preparation and 
LC settings remained unchanged and the MRM transitions 
of MS were set for specific masses of isotopically-labeled 
compounds, including spiked compounds and potential 
Fig. 1  Scheme of different CSF handling protocols. Temperature 
was different for protocol 1. Ethanol was added in protocols 2 and 3 
(striped pattern). Centrifugation was performed in protocols 1, 3 and 
5 (arrows). ILC-mix mix of isotopically-labeled compounds; EtOH 
ethanol
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degradation product of 13C2-glutamine namely 13C2-glu-
taminc acid. For normalization, the same ISTDs were used 
as for the endogenous equivalents. Similarly, the referred QC 
approach was applied. Calibration samples were prepared 
with pure standards of isotopically-labeled compounds, 
spiked at 7 consecutive twofold dilutions into aliquots of 
CSF pooled from all the study samples. Covered concentra-
tion ranges were: 3.75–240 µM for 13C2-alanine, 0.875–56 
µM for 13C15N-isoleucine, 65.5–4000 µM 13C2-glutamine, 
1.56–100 µM for U–13C15ND-glutamic acid and 0.0156–1 
µM for 13C6-dopamine HCl. Samples of CSF pool without 
any standard were used as zero point for the calibration. 
Absolute concentrations in µmol/L were calculated using 
linear calibration lines as previously described and imple-
mented in R package ‘chemCal’ (Massart et al. 1997).
2.6  Correction for volume differences
In protocols 2 and 3 the sampling procedure involved mix-
ing CSF and ILC-mix with ethanol. Potential in-accuracies 
in mixing of different volumes can lead to an increased 
variability of metabolites concentrations or a systematic 
bias in further analysis. Especially in protocol 2 the CSF 
volume is less controlled because CSF drips directly into a 
relatively large sampling tube already containing ethanol. 
In CSF samples from protocol 2 concentrations of almost 
every endogenous and isotopically-labeled metabolite were 
approximately 20% higher in comparison to samples from 
the other protocols (Fig. S-1). The fact that both endogenous 
(from CSF) and isotopically-labeled metabolites (from ILC-
mix) were increased indicated that there was less ethanol in 
samples from protocol 2 than anticipated. This systematic 
error could result from evaporation of ethanol before, during 
and after sampling, or might be caused by inconsistencies in 
pipetting of cooled volatile ethanol.
In order to test for differences in endogenous metabo-
lite levels between all five protocols, without the influence 
of the systematic error described above, we standardized 
concentrations of all endogenous metabolites to the con-
centrations of endogenous l-alanine and l-isoleucine (Fig. 
S-1). l-alanine and l-isoleucine are compounds with hardly 
any degradation ex-vivo (Davis et al. 2009). Concentrations 
of all isotopically-labeled compounds were standardized to 
the concentrations of 13C2-alanine and 13C15N-isoleucine in 
a special reference sample (ILC-mix with 1 mL of water 
instead of CSF, sampled and processed on the same day 
as clinical samples). See Supplemental Methods for full 
descriptions and examples of the applied corrections.
2.7  Statistical analysis
Relative concentrations of endogenous compounds and abso-
lute concentrations of stability markers were log-transformed 
prior to statistical analysis (Bland and Altman 1996; Sumner 
et al. 2007). To test for differences between the five pro-
tocols, we applied one-way repeated measures ANOVA. 
Reported p-values from repeated measures ANOVA were 
not corrected for multiple testing. P-values below 0.05 were 
considered significant. When significant, post-hoc pairwise 
t-test comparisons were applied with Bonferroni’s correc-
tion. The same ANOVA strategy was used to compare deg-
radation percentages of 13C2-glutamine to 13C2-glutamic 
acid (volume correction and log-transformation were not 
necessary for these data). Repeated measures ANOVA was 
performed with R software (package “ez” version 4.2-2).
3  Results
3.1  Sample set
We obtained CSF from 12 females and 9 males (mean 
age of 38.2 ± 12.2  years old). Routine CSF diagnos-
tics were performed and were all within reference lim-
its. Median erythrocyte count was 2.5 cells/3 µL (range 
0–200); mean leucocyte count 3.50 ± 2.50 cells/3 µL; mean 
total protein 0.33 ± 0.11  g/L; and mean glucose levels 
3.24 ± 0.19 mmol/L. With LC–MS we identified and quan-
tified 36 amino acids and 7 isotopically-labeled compounds.
3.2  Endogenous metabolites
There were no significant concentration differences between 
the sampling protocols for 31 out of 36 (86.1%) amines. Five 
amines showed significant differences: O-phosphoethanola-
mine (PE), gamma-aminobutyric acid (GABA), l-glutamic 
acid, l-methionine sulfoxide and l-aspartic acid (Table 1). 
PE concentrations were significantly lower in the protocols 
in which ethanol was used as additive (protocols 2 and 3) 
compared to protocols without ethanol (protocols 4 and 5; 
Fig. 2a). GABA concentrations were also lower in samples 
from protocols 2 and 3 (with ethanol) compared to samples 
from protocols 1 and 5 (without ethanol; Fig. 2b). However, 
GABA concentrations were primarily higher in samples pro-
cessed at room temperature (protocol 1) than in samples pro-
cessed on ice (protocols 2–5; Fig. 2b). Concentrations of PE, 
l-glutamic acid and l-methionine sulfoxide concentrations 
were also higher in protocol 1 (room temperature) but only 
compared to protocol 3 (on ice plus centrifugation; Fig. 2a, 
c, d). l-aspartic acid showed no significant differences in 
the post-hoc analysis (data not shown in Fig. 2). To exclude 
potential confounding effects of the volume correction, we 
performed an additional analysis in which we excluded pro-
tocol 2 and did not perform volume correction. This analysis 
showed the same effects for GABA, PE and l-glutamic acid 
(Table S-1).
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3.3  Labeled stability markers
There were no significant differences between protocols in 
concentrations of the stable (13C2-alanine, and 13C15N-iso-
leucine) and the potentially unstable isotopically-labeled 
markers (13C2-glutamine,  U13C–U15N–UD-glutamic acid, 
and 13C6-dopamine) (Table 2). We observed very low 
concentrations for 13C2-glutamic acid, the degradation 
product of 13C2-glutamine. Degradation ranged from 0.16 
to 0.17% of the original 13C2-glutamine levels with no 
difference between protocols. We did not detect degrada-
tion products of 13C6-dopamine. An additional analysis in 
which we excluded protocol 2 also showed no significant 
differences between protocols (Table S-2).
Table 1  Relative concentrations of endogenous amines per protocol after volume correction
Relative concentrations of endogenous compounds reported as response ratios to their respective internal standards. P-values from one-way 
repeated measures ANOVA. Metabolites sorted based on p-value (small to large). P-values < 0.05 are depicted in bold
SDMA symmetric dimethylarginine, ADMA asymmetric dimethylarginine
Metabolites Relative concentration p-value
Protocol 1 Protocol 2 Protocol 3 Protocol 4 Protocol 5
O-phosphoethanolamine 0.078 ± 0.02 0.071 ± 0.015 0.064 ± 0.014 0.078 ± 0.018 0.079 ± 0.017 < 0.001
Gamma-aminobutyric acid 0.0071 ± 0.0026 0.0049 ± 0.002 0.0052 ± 0.0024 0.0055 ± 0.0022 0.0057 ± 0.0024 < 0.001
l-glutamic acid 0.022 ± 0.009 0.02 ± 0.01 0.018 ± 0.007 0.020 ± 0.007 0.020 ± 0.009 0.017
l-methionine sulfoxide 0.016 ± 0.005 0.015 ± 0.006 0.014 ± 0.005 0.015 ± 0.004 0.014 ± 0.005 0.033
l-aspartic acid 0.055 ± 0.051 0.052 ± 0.068 0.051 ± 0.048 0.054 ± 0.043 0.050 ± 0.051 0.047
l-methionine 0.537 ± 0.123 0.544 ± 0.126 0.554 ± 0.132 0.534 ± 0.121 0.544 ± 0.121 0.124
SDMA 0.0039 ± 0.0009 0.0045 ± 0.0013 0.0044 ± 0.0016 0.0040 ± 0.0011 0.0041 ± 0.0012 0.168
l-isoleucine 0.013 ± 0.004 0.013 ± 0.003 0.013 ± 0.003 0.014 ± 0.004 0.013 ± 0.004 0.172
ADMA 0.0005 ± 0.0002 0.0006 ± 0.0003 0.0007 ± 0.0003 0.0006 ± 0.0003 0.0006 ± 0.0003 0.177
l-alanine 0.068 ± 0.016 0.069 ± 0.018 0.070 ± 0.018 0.068 ± 0.016 0.068 ± 0.017 0.208
l-threonine 1.359 ± 0.359 1.356 ± 0.368 1.383 ± 0.385 1.366 ± 0.363 1.396 ± 0.387 0.248
l-asparagine 0.322 ± 0.073 0.332 ± 0.078 0.327 ± 0.081 0.323 ± 0.074 0.326 ± 0.075 0.286
l-serine 2.574 ± 0.665 2.590 ± 0.776 2.625 ± 0.679 2.620 ± 0.636 2.660 ± 0.679 0.362
l-valine 0.037 ± 0.011 0.037 ± 0.011 0.037 ± 0.011 0.036 ± 0.011 0.037 ± 0.011 0.406
l-arginine 1.896 ± 0.458 1.931 ± 0.471 2.005 ± 0.56 1.898 ± 0.472 1.969 ± 0.492 0.432
l-lysine 3.221 ± 0.787 3.283 ± 0.806 3.305 ± 0.913 3.248 ± 0.746 3.306 ± 0.8 0.436
Ethanolamine 3.595 ± 0.562 3.726 ± 0.787 3.784 ± 0.873 3.739 ± 0.69 3.818 ± 0.642 0.447
l-proline 0.025 ± 0.018 0.025 ± 0.018 0.025 ± 0.016 0.025 ± 0.016 0.024 ± 0.016 0.455
Taurine 0.302 ± 0.085 0.320 ± 0.108 0.323 ± 0.132 0.307 ± 0.092 0.315 ± 0.096 0.465
l-kynurenine 0.0023 ± 0.0012 0.0025 ± 0.0016 0.0023 ± 0.0011 0.0024 ± 0.0011 0.0025 ± 0.0009 0.473
N6N6N6-trimethyl-l-lysine 0.0056 ± 0.0008 0.0056 ± 0.0013 0.0059 ± 0.0014 0.0058 ± 0.0011 0.006 ± 0.001 0.474
Putrescine 0.0082 ± 0.0025 0.0085 ± 0.0031 0.0087 ± 0.0035 0.0078 ± 0.0028 0.0084 ± 0.0029 0.526
l-leucine 0.018 ± 0.004 0.018 ± 0.004 0.018 ± 0.004 0.017 ± 0.004 0.018 ± 0.004 0.552
l-2-aminoadipic acid 0.0011 ± 0.0004 0.0011 ± 0.0004 0.0011 ± 0.0004 0.0011 ± 0.0004 0.0011 ± 0.0004 0.563
l-tryptophan 0.310 ± 0.064 0.323 ± 0.085 0.326 ± 0.082 0.312 ± 0.068 0.318 ± 0.065 0.588
Glycylglycine 0.021 ± 0.008 0.021 ± 0.005 0.020 ± 0.009 0.023 ± 0.015 0.022 ± 0.008 0.595
l-histidine 0.090 ± 0.016 0.094 ± 0.02 0.094 ± 0.025 0.092 ± 0.018 0.094 ± 0.018 0.651
l-glutamine 11.877 ± 2.061 12.231 ± 2.401 12.471 ± 2.977 12.217 ± 2.571 12.320 ± 2.696 0.665
l-alpha aminobutyric acid 0.072 ± 0.021 0.073 ± 0.023 0.074 ± 0.025 0.072 ± 0.021 0.074 ± 0.023 0.685
l-tyrosine 0.725 ± 0.154 0.751 ± 0.189 0.756 ± 0.219 0.73 ± 0.154 0.747 ± 0.169 0.790
Sarcosine 0.0010 ± 0.0003 0.0009 ± 0.0004 0.0010 ± 0.0005 0.0011 ± 0.0006 0.0011 ± 0.0006 0.852
Ornithine 0.200 ± 0.071 0.198 ± 0.087 0.199 ± 0.069 0.198 ± 0.066 0.199 ± 0.067 0.885
l-phenylalanine 0.023 ± 0.004 0.023 ± 0.005 0.023 ± 0.006 0.022 ± 0.004 0.023 ± 0.005 0.912
l-homoserine 0.0061 ± 0.0014 0.0060 ± 0.0011 0.0059 ± 0.0014 0.0060 ± 0.0017 0.0060 ± 0.001 0.937
Citrulline 0.04 ± 0.014 0.04 ± 0.015 0.04 ± 0.014 0.039 ± 0.014 0.04 ± 0.016 0.941
l-4-hydroxyproline 0.023 ± 0.013 0.024 ± 0.014 0.024 ± 0.014 0.023 ± 0.014 0.024 ± 0.015 0.947
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4  Discussion
When performing metabolomics in CSF we want our meas-
urements to reflect the in vivo situation as close as possible. 
It is therefore important to avoid ex vivo metabolism. The 
aim of this study was to investigate the effect of three major 
factors (low sampling and processing temperature, centrifu-
gation to remove cells, and the use of ethanol as additive to 
stop enzymatic reactions) on the stability of primary and 
secondary endogenous amines. To this end we compared 
five different CSF sample handling protocols. In addition, 
we aimed to quantify the degradation of allegedly unsta-
ble metabolites such as l-glutamine and l-glutamic acid by 
adding isotopically-labeled versions of these metabolites to 
sampling tubes before CSF sampling. We showed that the 
effects of different protocols were minimal, except for a clear 
effect of temperature (21 vs. 4 °C) on GABA, and effects of 
ethanol on PE and partly on GABA. In addition, our labeling 
strategy with isotopically-labeled compounds allowed us to 
successfully monitor degradation of l-glutamine to l-glu-
tamic acid and showed that the amount of degradation was 
extremely minimal, with no difference between protocols.
Our observation that most endogenous amines are stable 
under controlled sampling conditions with minimal delay in 
sample storage is in line with other large scale stability stud-
ies which have measured multiple amino acids in CSF (Fer-
raro and Hare 1984; Lundqvist et al. 1989; Rosenling et al. 
2009, 2011). In addition, the fact that the reported CSF con-
centrations of most amines are quite similar over different 
studies also indicates that most endogenous amines in CSF 
are stable, despite varying methodologies for sample han-
dling and measurement (Lundqvist et al. 1989). However, 
Fig. 2  Scatter plots of metabolites with significant protocol differ-
ences. Relative concentrations reported as response ratios to their 
respective internal standards. a O-phosphoethanolamine: significant 
differences between protocol 1 (*) and protocol 3 (p-value = 0.007); 
between protocol 2 (*) and protocols 4 (p-value = 0.041) and 5 
(p-value = 0.006); and between protocol 3 (‡) and protocols 4 
(p-value = 0.001) and 5 (p-value < 0.001). b Gamma-aminobutyric 
acid: significant differences between protocol 1 (*) and proto-
cols 2–5 (p-value < 0.001 for all comparisons); between protocol 2 
(+) and protocols 4 (p-value = 0.027) and 5 (p-value = 0.014); and 
between protocol 3 (‡) and protocol 5 (p-value < 0.001). c l-glutamic 
acid: significant difference between protocol 1 (*) and protocol 3 
(p-value = 0.004). d l-methionine sulfoxide: significant difference 
between protocol 1 (*) and protocol 3 (p-value = 0.016)
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glutamic acid is an important exception given that reported 
concentrations in CSF vary widely between studies (Ferra-
rese et al. 1993; Lundqvist et al. 1989). Additionally, studies 
investigating the stability of glutamic acid report varying 
results which suggests that glutamic acid concentrations 
might be unstable in CSF (Anesi et al. 1998; Ferrarese et al. 
1993).
The ex vivo non-enzymatic (chemical) degradation of 
l-glutamine to l-glutamic acid is negligible. Studies meas-
uring l-glutamine degradation in water showed that there is 
only a small amount of non-enzymatic degradation at room 
temperature (< 1% if left at room temperature for more than 
15 days) and no observable decrease at − 80 °C (Khan and 
Elia 1991; Snowden et al. 2002). More importantly, degrada-
tion did not result in the formation of glutamic acid; instead 
it presumably resulted in formation of pyroglutamic acid. 
Only after heating to 100 °C, small amounts of glutamic acid 
were detected (Snowden et al. 2002).
The ex vivo enzymatic conversion of l-glutamine and 
l-glutamic acid is therefore the most important factor lead-
ing to the alleged instability of these compounds (Ferraro 
and Hare 1984). When left at room temperature, glutamic 
acid levels in untreated CSF steadily increased and double 
within 24 h (Ferrarese et al. 1993; Ferraro and Hare 1984; 
Rosenling et al. 2009, 2011). The time-related glutamic acid 
changes in CSF suggests enzymatic processes that mediate 
the slow formation of new glutamic acid from glutamine 
or proteins (Ferrarese et al. 1993). Different additives have 
been tried to deproteinize CSF, such as by trichloroacetic 
acid (Anesi et al. 1998), sulfosalicylic acid (Lakke and Teel-
ken 1976), or perchloric acid (Lundqvist et al. 1989), how-
ever, this led to conflicting results because acidic conditions 
also cause other chemical reactions and release of bound 
amino acids.
The labeling strategy applied in this study allowed the 
selective monitoring of the conversion of l-glutamine to 
l-glutamic acid. We observed almost no degradation from 
13C2-glutamine to 13C2-glutamic acid. Because the concen-
tration of l-glutamine in CSF is approximately thousand 
times higher than l-glutamic acid, it is theoretically still 
possible that minimal degradation of l-glutamine is affect-
ing l-glutamic acid concentrations. However, since we did 
not observe significant protocol differences for isotopically-
labeled compounds (13C2-glutamine, 13C2-glutamic acid and 
 U13C–U15N–UD-glutamic acid) the impact will be similar 
for all protocols.
The rate of chemical and enzymatic activity is highly 
dependent on the sample temperature, which combined with 
a delayed storage determines the actual degree of change 
(Ferrarese et al. 1993; Ferraro and Hare 1984). The effect of 
delayed storage was minimal in our study because all sam-
ples were placed on dry ice within 1 h and stored at − 80 °C 
within 2 h. We did observe a clear effect of temperature on 
GABA concentrations, which were higher at room tempera-
ture (protocol 1) compared to samples that were processed 
at 4 °C (other protocols). The increase of GABA at room 
temperature is in line with previous reports on GABA sta-
bility (Ferraro and Hare 1984; Grossman et al. 1980) and is 
thought to be secondary to enzymatic hydrolysis of GABA-
containing peptides (Hare et al. 1981). We also observed 
significant higher levels of endogenous l-glutamic acid 
and l-methionine sulfoxide in samples at room temperature 
(protocol 1) compared to cooled samples containing ethanol 
(protocol 3). Taken together, the effect of temperature seems 
Table 2  Labeled stability markers per protocol after volume correction
P-values from one-way repeated measures ANOVA
a Volume correction was not necessary since both glutamine and glutamic acid were measured in the same volume
Metabolites Absolute concentration (µmol/L) p-value
Protocol 1 Protocol 2 Protocol 3 Protocol 4 Protocol 5
Stable markers
 2,3-13C2-alanine 28.89 ± 0.3 28.77 ± 0.39 28.84 ± 0.41 28.88 ± 0.32 28.77 ± 0.22 0.564
 13C15N-isoleucine 6.22 ± 0.07 6.24 ± 0.09 6.23 ± 0.09 6.22 ± 0.07 6.24 ± 0.05 0.567
Unstable markers
 1,3-13C2-glutamine 453.6 ± 18.17 467.1 ± 53.57 455.99 ± 50.93 454.01 ± 11.79 450.37 ± 16.62 0.613
 13C2-glutamic acid 0.72 ± 0.06 0.75 ± 0.08 0.72 ± 0.08 0.75 ± 0.07 0.75 ± 0.07 0.101
 U13C-U15N-UD-glutamic acid 11.44 ± 0.36 11.64 ± 0.66 11.32 ± 0.89 11.56 ± 0.30 11.57 ± 0.33 0.125
 1,2,3,4,5,6-13C6-dopamine 0.11 ± 0.01 0.11 ± 0.02 0.11 ± 0.02 0.11 ± 0.01 0.10 ± 0.01 0.508
Metabolites Conversion from glutamine to glutamic acid (%) p-value
Protocol 1 Protocol 2 Protocol 3 Protocol 4 Protocol 5
Degradationa
 1,3-13C2-glutamine to 13C2-glutamic acid (%) 0.158 ± 0.012 0.162 ± 0.026 0.160 ± 0.027 0.165 ± 0.015 0.166 ± 0.017 0.346
 M. J. Noga et al.
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limited for most of the metabolites provided that the CSF 
samples are processed quickly, cooled to − 20 °C within 1 h 
and stored at − 80 °C within 2 h. In conclusion, it is advis-
able to quickly cool CSF samples and perform sample pro-
cessing at 4 °C to reduce enzymatic activity, which seems 
especially relevant for GABA.
Immune cells, either native to CSF or artificially intro-
duced due to blood contamination during sampling may be 
present in CSF (Rosenling et al. 2009). Removing cells is 
also expected to limit effects of enzymatic and metabolic 
activity in CSF, and in addition reduces the risk of con-
tamination of CSF with cytoplasmic metabolites due to cell 
lysis during storage at − 80 °C (Rosenling et al. 2009). In 
our study we did not observe a clear impact of centrifuga-
tion. This might be due to the fact that contamination of 
CSF samples with blood was minimal, as evidenced by the 
low red blood cell count in our samples. As even minor con-
tamination can have a major impact on the metabolic pro-
file (Rosenling et al. 2009), we advise a centrifugation step 
immediately after withdrawal of CSF.
Ethanol was used in this study because it has a non-spe-
cific denaturation effect on all enzymes and will reduce or 
stop their activity; this inactivates most of the metabolic 
reactions and thereby, in theory, should stabilize the CSF 
metabolome (Alfredsson and Sedvall 1983; Alfredsson et al. 
1988). However, the effect of ethanol for the metabolites 
analyzed in this study was small; the two protocols contain-
ing ethanol (protocols 2 and 3) showed slightly lower con-
centrations of PE (decrease of 19%) and GABA (decrease of 
9%) compared to the other protocols (Table 1). Ex vivo PE 
and GABA are known as degradation products of phospho-
lipids and GABA-containing peptides, respectively (Gross-
man et al. 1980; Hare et al. 1981). Sampling into pre-cooled 
ethanol (protocol 2) causes rapid cooling and inactivation of 
enzymes, however, this procedure had only small advantages 
compared with protocol 3. Still, addition of ethanol allows 
in principle aliquoting of samples below 0 °C, as the melt-
ing of water/ethanol mixtures is below 0 °C. A downside to 
the addition of stabilizing agents such as ethanol is an addi-
tional step in the procedure and it may lead to distortions in 
metabolomics measurements such as reported for NMR (van 
der Sar et al. 2015). So despite the theoretical benefits of 
adding ethanol its positive effects seem minimal under these 
controlled sampling conditions and therefore not considered 
necessary for the class of metabolites studied. However, for 
more unstable metabolite classes the addition of ethanol 
could still be beneficial and needs further investigation.
The major strength of this study was that we were able to 
monitor ex vivo degradation of selected metabolites by add-
ing them as isotopically-labeled markers to sampling tubes. 
Because of this addition we were also able to detect volume 
effects, which otherwise might have been mistaken for sta-
bility effects. A possible limitation of this labeling strategy 
is that some of the degradation of isotopically-labeled com-
pounds occurred before CSF was added; additionally there 
might be some impurity of the isotopically-labeled standards 
that is within the limits of industrial quality. However, this 
would not affect the validity of our study, because prepara-
tion of the ILC-mix was performed in one batch, and for 
each subject we used one aliquot of the ILC-mix, which was 
thawed just before sampling. Furthermore, preparation of the 
sampling tubes with ILC-mix was highly standardized, and 
there were no differences between protocols in time between 
preparation of sampling tubes and CSF sampling. Nonethe-
less, if degradation of the ILC-mix had occurred prior to 
CSF sampling, this would have resulted in an overestimation 
of degradation; the observed degradation of 13C2-glutamine 
to 13C2-glutamic acid can therefore be considered an upper 
limit of degradation. The unique labeling strategy used in 
this study could benefit future studies addressing stability 
issues of other metabolites, because it allows detection of 
degradation during sampling and sample handling with a 
higher sensitivity and selectivity than just studying endog-
enous metabolites.
An important limitation of the study is that it does not 
fully reflect circumstances as they occur in clinical prac-
tice. In our study samples were processed relatively fast and 
were in the freezer within 2 h. In clinical practice samples 
often have to be transported, i.e. from the outpatient clinic 
to the laboratory for centrifugation or to special freezer loca-
tions. This study, therefore, does not provide information 
on effects of temperature, centrifugation or ethanol addition 
when sample processing takes longer than 2 h. Neither did 
we investigate effects of tube transfer or extra freeze–thaw 
cycles before metabolome analysis. Complications that can 
both occur in research and diagnostic settings and could be 
addressed in future studies.
5  Conclusion
We have evaluated five different CSF sampling protocols, 
including an innovative sampling protocol which uses etha-
nol as preservative, on stability of endogenous amines. The 
effects of centrifugation, temperature and addition of ethanol 
were minimal for most amines, with the exception of PE, 
GABA and to a lesser extent l-glutamic acid. In addition, 
we showed that ex vivo degradation of l-glutamine to l-glu-
tamic acid under controlled conditions is very limited. Taken 
together, we conclude that the consensus guideline for sam-
pling CSF as was previously published (Del Campo et al. 
2012) is adequate for most amines (at least for metabolites 
included in this study), provided that samples are cooled to 
4 °C immediately after collection, centrifuged, and stored 
at − 80 °C within 2 h.
Strategies to assess and optimize stability of endogenous amines during cerebrospinal fluid…
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